Alteplase | Plasminogen activator (rt-PA) | Therapeutic Glycoprotein

Aliquoted from the original drug | Now available for research use

Aliquots of the reference drug Alteplase are now available as research consumables.

Alteplase drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.

Not looking for Alteplase Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Actilyse® / Alteplase Reference Product

Drug nameActilyse®
INNAlteplase
API typeGlycoprotein
Pharmacotherapeutic group
Antithrombotic agents
ATC code
B01AD02
Target
Plasminogen activator (rt-PA)
General functionTreat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter.
Short description
Pharmacodynamic properties
(Mechanism of action; Source www.medicines.org.uk)
The active ingredient of Actilyse is alteplase a recombinant human tissue-type plasminogen activator, a glycoprotein, which activates plasminogen directly to plasmin. When administered intravenously, alteplase remains relatively inactive in the circulatory system. Once bound to fibrin, it is activated, inducing the conversion of plasminogen to plasmin leading to the dissolution of the fibrin clot.
Pharmacodynamic properties (Pharmacodynamic effects; Source www.medicines.org.uk)Due to its relative fibrin-specificity alteplase at a dose of 100 mg leads to a modest decrease of the circulating fibrinogen levels to about 60 % at 4 hours, which is generally reverted to more than 80 % after 24 hours. Plasminogen and alpha-2-antiplasmin decrease to about 20 % and 35 % respectively after 4 hours and increase again to more than 80 % at 24 hours. A marked and prolonged decrease of the circulating fibrinogen level is only seen in few patients.
Original license holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Marketing authorisation numbers
PL 14598/0183
Marketing authorisation holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Name of the manufacturer of the biological active substance
Information not available
Name and address of the manufacturer(s) responsible for batch releaseInformation not available
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
Powder
Arginine
Phosphoric acid (for pH adjustment)
Polysorbate 80

Solvent
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting